Given these findings, early postoperative assessment of PD-L1 expression and driver alterations (e.g., EGFR, ALK) is now recommended for patients with the p-stage II or higher NSCLC to optimize adjuvant therapy selection. This evidence concerns the gene ALK and non-small cell lung carcinoma.